MD Anderson Partners With Brazilian Hospital To Eliminate Cancer Globally

Hospital Israelita Albert EinsteinThe University of Texas MD Anderson Cancer Center recently partnered with Brazilian-based Hospital Israelita Albert Einstein (HIAE) to pioneer multidisciplinary cancer patient care in Brazil, while meeting MD Anderson’s goal of eliminating cancer on a global scale.

The private hospital, located in São Paulo, is one of the most respected health institutions in Latin America. HIAE began investing in cutting-edge medical technology early on, and by the 1970s it had acquired the first two magnetic resonance imaging (MRI) devices in Latin America. Today, the hospital continues to be a healthcare technology leader in the region, having acquired the da Vinci Surgical System in July 2007. Last December, HIAE opened a new Oncology and Hematology Center, modeled after MD Anderson’s facilities.

Having received specialized training and guidance from MD Anderson to help develop its oncology program since 2008, the Brazilian hospital will now be the first clinical extension of MD Anderson in Latin America and the first international member of the MD Anderson Cancer Network, a select group of hospitals and health systems with access to best practices, education, research, and treatment protocols developed at MD Anderson.

MD Anderson’s president Ronald DePinho recognizes HIAE’s “exceptional physicians, state-of-the-art facilities and high quality care,” adding that MD Anderson will combine its vast cancer expertise with HIAE’s excellence.

MD Anderson’s goal, explains vice president of business development Amy Hay, will be to address the over half a million cancer cases registered in Brazil every year by delivering advanced, research-driven multidisciplinary care.

With HIAE integrated into MD Anderson’s network, patients in Brazil will have access to a multidisciplinary and multi specialty cancer center with outpatient care, advanced treatment technologies, and a full range of support services that will include medical, radiation, and surgical oncology, as well as pathology, laboratory, diagnostic imaging, and other supportive clinical services.

In addition to these services, HIAE will be provided with clinical care oversight, order sets, and treatment algorithms. The clinical integration will also include planning and clinical program support, faculty and staff education and training, quality measurement and reporting tools, access to clinical trials, and research collaborations.

About Chris Comish

Chris Comish
Chris Comish is the Publisher, President, and CEO of BioNews Texas. He is an influencer in the Texas biotech industry and guides the editorial and content direction of the publication.
Scroll To Top